

What is claimed is:

CLAIMS

1. A pharmaceutical composition for treatment of chronic rheumatoid arthritis containing an interleukin-6 antagonist as an effective component.
- 5 2. A pharmaceutical composition for treatment of chronic rheumatoid arthritis according to claim 1, characterized in that said interleukin-6 antagonist suppresses abnormal growth of synovial cells occurring with chronic rheumatoid arthritis.
- 10 3. A pharmaceutical composition for treatment of chronic rheumatoid arthritis according to claim 1, characterized in that said interleukin-6 antagonist is an antibody against interleukin-6.
- 15 4. A pharmaceutical composition for treatment of chronic rheumatoid arthritis according to claim 2, characterized in that said interleukin-6 is human interleukin-6.
- 20 5. A pharmaceutical composition for treatment of chronic rheumatoid arthritis according to claim 1, characterized in that said interleukin-6 antagonist is an antibody against interleukin-6 receptor.
- 25 6. A pharmaceutical composition for treatment of chronic rheumatoid arthritis according to claim 2, characterized in that said interleukin-6 receptor is human interleukin-6 receptor.
7. A synovial cell growth inhibitor containing an interleukin-6 antagonist as an effective component.
8. A synovial cell growth inhibitor according to claim 7, characterized in that said interleukin-6 antagonist is interleukin-6 antibody or interleukin-6 receptor antibody.

add  
add  
27

103